ESH CLL 2022 | The importance of TP53 testing in CLL
Lukas Frenzel
• 22 Mar 2022
In this video, Lukas Frenzel, MD, University of Cologne, Cologne, Germany, discusses the importance of testing for TP53 mutation when making treatment decisions in chronic lymphocytic leukemia (CLL). Dr Frenzel explains that patients with TP53 mutation are not good candidates for chemotherapy and should be treated with Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors. Dr Frenzel then outlines the role of TP53 as a master regulator of apoptosis, and the role that this gene plays in influencing patient response to various therapies. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
Disclosures
Abbvie Advisory board
